Senza5 CART5 to enhance immunotherapy against T cell non-Hodgkin lymphoma

Brief description of study

To determine the safety profile and recommended phase II dose (RP2D) for Senza5 CART5 in participants with CD5+ nodal T cell lymphoma following lymphodepletion with cyclophosphamide and fludarabine. recommended phase II dose of Senza5 CART5 (investigational product) maximum tolerated dose of Senza5 CART5 (investigational product); response rates to investigational therapy including overall response rate, complete response, progression-free survival, overall survival, and duration of response

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 853503

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).